18.44 USD
+0.28 (+1.54%)
PHAR gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. PHAR is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PHAR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year PHAR has reported negative net income.
- PHAR had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: PHAR reported negative net income in multiple years.
- In multiple years PHAR reported negative operating cash flow during the last 5 years.
1.2 Ratios
- PHAR has a better Return On Assets (0.08%) than 88.45% of its industry peers.
- The Return On Equity of PHAR (0.14%) is better than 89.96% of its industry peers.
- PHAR has a Return On Invested Capital of 7.46%. This is amongst the best in the industry. PHAR outperforms 93.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.14% | ||
| ROIC | 7.46% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PHAR's Profit Margin of 0.11% is amongst the best of the industry. PHAR outperforms 88.64% of its industry peers.
- The Operating Margin of PHAR (10.06%) is better than 91.67% of its industry peers.
- PHAR's Gross Margin of 89.90% is amongst the best of the industry. PHAR outperforms 92.23% of its industry peers.
- In the last couple of years the Gross Margin of PHAR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.06% | ||
| PM (TTM) | 0.11% | ||
| GM | 89.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PHAR is creating some value.
- Compared to 1 year ago, PHAR has more shares outstanding
- Compared to 5 years ago, PHAR has more shares outstanding
- Compared to 1 year ago, PHAR has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 4.33 indicates that PHAR is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 4.33, PHAR is in the better half of the industry, outperforming 72.16% of the companies in the same industry.
- PHAR has a debt to FCF ratio of 2.49. This is a good value and a sign of high solvency as PHAR would need 2.49 years to pay back of all of its debts.
- The Debt to FCF ratio of PHAR (2.49) is better than 93.56% of its industry peers.
- PHAR has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
- PHAR has a Debt to Equity ratio of 0.46. This is in the lower half of the industry: PHAR underperforms 70.08% of its industry peers.
- Although PHAR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Altman-Z | 4.33 |
ROIC/WACC1.07
WACC7%
2.3 Liquidity
- A Current Ratio of 3.16 indicates that PHAR has no problem at all paying its short term obligations.
- PHAR has a Current ratio of 3.16. This is in the lower half of the industry: PHAR underperforms 62.50% of its industry peers.
- PHAR has a Quick Ratio of 2.39. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
- PHAR's Quick ratio of 2.39 is on the low side compared to the rest of the industry. PHAR is outperformed by 69.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.39 |
3. Growth
3.1 Past
- PHAR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.30%, which is quite impressive.
- Looking at the last year, PHAR shows a very strong growth in Revenue. The Revenue has grown by 26.78%.
- PHAR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
3.2 Future
- PHAR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.48% yearly.
- The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.
EPS Next Y234.87%
EPS Next 2Y104.54%
EPS Next 3Y59.38%
EPS Next 5Y53.48%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- PHAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- With a Price/Forward Earnings ratio of 64.00, PHAR can be considered very expensive at the moment.
- 89.58% of the companies in the same industry are more expensive than PHAR, based on the Price/Forward Earnings ratio.
- PHAR is valuated expensively when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 64 |
4.2 Price Multiples
- 93.56% of the companies in the same industry are more expensive than PHAR, based on the Enterprise Value to EBITDA ratio.
- 94.70% of the companies in the same industry are more expensive than PHAR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.03 | ||
| EV/EBITDA | 22.57 |
4.3 Compensation for Growth
- PHAR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of PHAR may justify a higher PE ratio.
- PHAR's earnings are expected to grow with 59.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.54%
EPS Next 3Y59.38%
5. Dividend
5.1 Amount
- PHAR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:PHAR (1/16/2026, 8:00:00 PM)
18.44
+0.28 (+1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners21.51%
Inst Owner Change0%
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap1.26B
Revenue(TTM)362.27M
Net Income(TTM)383.00K
Analysts88.57
Price Target19.77 (7.21%)
Short Float %0.04%
Short Ratio1.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.41%
PT rev (3m)-16.76%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)201.58%
EPS NY rev (1m)-27.86%
EPS NY rev (3m)-52.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.7%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)6.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 64 | ||
| P/S | 3.49 | ||
| P/FCF | 24.03 | ||
| P/OCF | 23.75 | ||
| P/B | 4.77 | ||
| P/tB | 9.74 | ||
| EV/EBITDA | 22.57 |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.29
Fwd EY1.56%
FCF(TTM)0.77
FCFY4.16%
OCF(TTM)0.78
OCFY4.21%
SpS5.29
BVpS3.86
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.14% | ||
| ROCE | 9.44% | ||
| ROIC | 7.46% | ||
| ROICexc | 13.1% | ||
| ROICexgc | 33.95% | ||
| OM | 10.06% | ||
| PM (TTM) | 0.11% | ||
| GM | 89.9% | ||
| FCFM | 14.51% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 4% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 5.94 | ||
| Cash Conversion | 102.18% | ||
| Profit Quality | 13727.2% | ||
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.39 | ||
| Altman-Z | 4.33 |
F-Score7
WACC7%
ROIC/WACC1.07
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y234.87%
EPS Next 2Y104.54%
EPS Next 3Y59.38%
EPS Next 5Y53.48%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%
EBIT growth 1Y355.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year401.72%
EBIT Next 3Y93.29%
EBIT Next 5Y78.86%
FCF growth 1Y309.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325.01%
OCF growth 3YN/A
OCF growth 5YN/A
PHARMING GROUP NV - ADR / PHAR FAQ
Can you provide the ChartMill fundamental rating for PHARMING GROUP NV - ADR?
ChartMill assigns a fundamental rating of 6 / 10 to PHAR.
What is the valuation status for PHAR stock?
ChartMill assigns a valuation rating of 6 / 10 to PHARMING GROUP NV - ADR (PHAR). This can be considered as Fairly Valued.
Can you provide the profitability details for PHARMING GROUP NV - ADR?
PHARMING GROUP NV - ADR (PHAR) has a profitability rating of 6 / 10.
Can you provide the financial health for PHAR stock?
The financial health rating of PHARMING GROUP NV - ADR (PHAR) is 7 / 10.